147 related articles for article (PubMed ID: 8289494)
1. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
[TBL] [Abstract][Full Text] [Related]
2. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Klumper E; Pieters R; den Boer ML; Huismans DR; Loonen AH; Veerman AJ
Br J Cancer; 1995 Jun; 71(6):1188-93. PubMed ID: 7779709
[TBL] [Abstract][Full Text] [Related]
3. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G; Zimmermann M; Janka-Schaub G;
Pediatr Blood Cancer; 2013 Feb; 60(2):254-7. PubMed ID: 22948968
[TBL] [Abstract][Full Text] [Related]
5. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
[TBL] [Abstract][Full Text] [Related]
6. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
Klumper E; Pieters R; Kaspers GJ; Huismans DR; Loonen AH; Rottier MM; van Wering ER; van der Does-van den Berg A; Hählen K; Creutzig U
Leukemia; 1995 Nov; 9(11):1864-9. PubMed ID: 7475276
[TBL] [Abstract][Full Text] [Related]
7. Superior cytotoxic potency of mitoxantrone in interaction with DNA: comparison with that of daunorubicin.
Fukushima T; Kawai Y; Nakayama T; Yamauchi T; Yoshida A; Urasaki Y; Imamura S; Kamiya K; Tsutani H; Ueda T; Nakamura T
Oncol Res; 1996; 8(2):95-100. PubMed ID: 8859780
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
9. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.
Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
Leuk Lymphoma; 1995 Nov; 19(5-6):407-16. PubMed ID: 8590840
[TBL] [Abstract][Full Text] [Related]
10. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
11. Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Kristensen J; Nygren P; Liliemark J; Fridborg H; Killander A; Simonsson B; Oberg G; Larsson R
Leukemia; 1994 Oct; 8(10):1712-7. PubMed ID: 7934168
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.
Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ
Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505
[TBL] [Abstract][Full Text] [Related]
13. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
[TBL] [Abstract][Full Text] [Related]
14. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia.
Maung ZT; Hogarth L; Reid MM; Proctor SJ; Hamilton PJ; Hall AG
Leukemia; 1994 Sep; 8(9):1487-91. PubMed ID: 8090028
[TBL] [Abstract][Full Text] [Related]
15. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
16. Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin.
Styczynski J; Wysocki M; Balwierz W; Kowalczyk JR
Leukemia; 2002 May; 16(5):820-5. PubMed ID: 11986942
[TBL] [Abstract][Full Text] [Related]
17. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
[TBL] [Abstract][Full Text] [Related]
18. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F
Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963
[TBL] [Abstract][Full Text] [Related]
20. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]